BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
A Study Investigating the Utilization, Effectiveness and Quality of Life in Clinical Practice in Germany for Participants With Relapsing-remitting Multiple Sclerosis Treated With Ozanimod (Zeposia®)
- First Posted Date
- 2022-04-19
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 450
- Registration Number
- NCT05335031
- Locations
- 🇩🇪
Universitätsklinikum Dresden, MS Ambulanz, Dresden, Saxony, Germany
A Study of the Effectiveness and Safety of Nivolumab Plus Chemotherapy in Participants With Untreated Advanced/Recurrent Gastric Cancer
- Conditions
- Stomach Neoplasms
- First Posted Date
- 2022-04-19
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 500
- Registration Number
- NCT05334719
- Locations
- 🇯🇵
Local Institution - 0001, Minato-ku, Tokyo, Japan
A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer
- Conditions
- Colorectal Neoplasms
- Interventions
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 700
- Registration Number
- NCT05328908
- Locations
- 🇧🇪
Local Institution - 0120, Leuven, Belgium
🇨🇭Local Institution - 0057, Aarau, AG, Switzerland
🇧🇪Local Institution - 0070, Edegem, Belgium
A Study of Yervoy and Opdivo Combination Therapy in Participants With Unresectable Advanced/Recurrent Malignant Pleural Mesothelioma (MPM)
- Conditions
- Mesothelioma, Malignant
- First Posted Date
- 2022-04-12
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 75
- Registration Number
- NCT05324436
- Locations
- 🇯🇵
Local Institution, Shinjuku-ku, Tokyo, Japan
A Study to Evaluate the Effect of Activated Charcoal With Sorbitol on the Single-dose of Mavacamten in Healthy Participants
- Conditions
- Healthy Participants
- Interventions
- Drug: Activated Charcoal with Sorbitol
- First Posted Date
- 2022-04-11
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 45
- Registration Number
- NCT05320094
- Locations
- 🇺🇸
Local Institution - 0001, Dallas, Texas, United States
A Study to Assess Relative Bioavailability of Branebrutinib, From a Tablet Formulation to the Capsule Formulation, the Effect of Food on the Bioavailability of Branebrutinib From a Tablet Formulation, and the Safety and Drug Levels of Branebrutinib From a Tablet Formulation in Healthy Participants
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2023-02-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 56
- Registration Number
- NCT05303220
- Locations
- 🇺🇸
Local Institution - 0001, Miami, Florida, United States
Expanded Access for Bromodomain and Extra-Terminal (BET) Inhibitor
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2022-10-14
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT05301972
A Study to Assess the Drug Interaction Between MYK-224 and Itraconazole and Verapamil in Healthy Participants
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2023-01-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 45
- Registration Number
- NCT05304533
- Locations
- 🇺🇸
Local Institution - 0001, Dallas, Texas, United States
A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors
- Conditions
- Advanced Cancer
- Interventions
- First Posted Date
- 2022-03-28
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 154
- Registration Number
- NCT05298592
- Locations
- 🇺🇸
Local Institution - 0021, Birmingham, Alabama, United States
🇺🇸University California San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, California, United States
A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection
- First Posted Date
- 2022-03-28
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 14
- Registration Number
- NCT05297565
- Locations
- 🇦🇺
Local Institution - 0008, Bendigo, Victoria, Australia
🇦🇺Local Institution - 0038, Coffs Harbour, New South Wales, Australia
🇺🇸Local Institution - 0004, Fort Wayne, Indiana, United States